UBS AM

UBS AM’s Pacira BioSciences PCRX Stock Holding History

UBS AM’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.67M	Buy	74,070 +605	+0.8%	+$13.4K	﹤0.01%	2125
2025 Q4	$1.9M	Sell	73,465 -2,832	-4%	-$67.3K	﹤0.01%	1895
2025 Q3	$1.97M	Sell	76,297 -65,839	-46%	-$1.62M	﹤0.01%	1760
2025 Q2	$3.4M	Buy	142,136 +47,706	+51%	+$1.2M	﹤0.01%	1896
2025 Q1	$2.35M	Sell	94,430 -10,425	-10%	-$250K	﹤0.01%	1917
2024 Q4	$1.98M	Buy	104,855 +21,781	+26%	+$382K	﹤0.01%	2053
2024 Q3	$1.25M	Sell	83,074 -22,839	-22%	-$390K	﹤0.01%	2282
2024 Q2	$3.03M	Buy	105,913 +55,777	+111%	+$1.59M	﹤0.01%	1770
2024 Q1	$1.46M	Hold	50,136	–	–	﹤0.01%	1831
2023 Q4	$1.69M	Hold	50,136	–	–	﹤0.01%	1773
2023 Q3	$1.54M	Buy	50,136 +2,326	+5%	+$83.8K	﹤0.01%	1743
2023 Q2	$1.95M	Hold	47,810	–	–	﹤0.01%	1663
2023 Q1	$1.95M	Buy	47,810 +4,618	+11%	+$184K	﹤0.01%	1663
2022 Q4	$1.67M	Hold	43,192	–	–	﹤0.01%	1612
2022 Q3	$2.3M	Sell	43,192 -10,735	-20%	-$597K	﹤0.01%	1529
2022 Q2	$3.14M	Buy	53,927 +525	+1%	+$34.4K	﹤0.01%	1411
2022 Q1	$4.08M	Buy	53,402 +2,511	+5%	+$167K	﹤0.01%	1448
2021 Q4	$3.06M	Hold	50,891	–	–	﹤0.01%	1658
2021 Q3	$2.85M	Hold	50,891	–	–	﹤0.01%	1673
2021 Q2	$3.09M	Buy	50,891 +3,680	+8%	+$233K	﹤0.01%	1646
2021 Q1	$3.31M	Sell	47,211 -421	-0.9%	-$30.1K	﹤0.01%	1527
2020 Q4	$2.85M	Buy	47,632 +3,425	+8%	+$201K	﹤0.01%	1543
2020 Q3	$2.66M	Buy	44,207 +2,568	+6%	+$149K	﹤0.01%	1429
2020 Q2	$2.18M	Sell	41,639 -6,038	-13%	-$252K	﹤0.01%	1487
2020 Q1	$1.6M	Sell	47,677 -197	-0.4%	-$8.18K	﹤0.01%	1505
2019 Q4	$2.17M	Buy	47,874 +241	+0.5%	+$10.2K	﹤0.01%	1569
2019 Q3	$1.81M	Buy	47,633 +4,088	+9%	+$163K	﹤0.01%	1650
2019 Q2	$1.89M	Buy	43,545 +7,562	+21%	+$321K	﹤0.01%	1621
2019 Q1	$1.37M	Buy	35,983 +1,643	+5%	+$64.1K	﹤0.01%	1689
2018 Q4	$1.48M	Buy	34,340 +4,983	+17%	+$233K	﹤0.01%	1562
2018 Q3	$1.44M	Hold	29,357	–	–	﹤0.01%	1643
2018 Q2	$941K	Buy	29,357 +3,426	+13%	+$118K	﹤0.01%	1832
2018 Q1	$808K	Buy	25,931 +7,031	+37%	+$250K	﹤0.01%	1855
2017 Q4	$863K	Sell	18,900 -5,564	-23%	-$221K	﹤0.01%	1803
2017 Q3	$919K	Buy	24,464 +292	+1%	+$11.8K	﹤0.01%	1743
2017 Q2	$1.15M	Sell	24,172 -151,120	-86%	-$7.01M	﹤0.01%	1600
2017 Q1	$7.99M	Buy	175,292 +4,592	+3%	+$198K	0.01%	932
2016 Q4	$5.51M	Sell	170,700 -21,390	-11%	-$714K	0.01%	977
2016 Q3	$6.57M	Sell	192,090 -5,516	-3%	-$216K	0.01%	969
2016 Q2	$6.67M	Buy	197,606 +64,284	+48%	+$3.16M	0.01%	959
2016 Q1	$7.06M	Sell	133,322 -9,868	-7%	-$577K	0.01%	938
2015 Q4	$11M	Buy	143,190 +41,354	+41%	+$2.34M	0.01%	838
2015 Q3	$4.19M	Buy	101,836 +15,778	+18%	+$966K	﹤0.01%	1122
2015 Q2	$6.08M	Buy	86,058 +59	+0.1%	+$4.65K	0.01%	1015
2015 Q1	$7.64M	Sell	85,999 -500	-0.6%	-$50.7K	0.01%	950
2014 Q4	$7.67M	Buy	86,499 +12,400	+17%	+$1.17M	0.01%	942
2014 Q3	$7.18M	Sell	74,099 -700	-0.9%	-$68.1K	0.01%	948
2014 Q2	$6.87M	Sell	74,799 -6,600	-8%	-$503K	0.01%	962
2014 Q1	$5.7M	Sell	81,399 -3,900	-5%	-$265K	0.01%	1008
2013 Q4	$4.9M	Sell	85,299 -86,900	-50%	-$4.57M	0.01%	1014
2013 Q3	$8.28M	Buy	172,199 +11,800	+7%	+$430K	0.01%	852
2013 Q2	$4.65M	Buy	+160,399	New	+$4.64M	0.01%	975

Other funds holding PCRX

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Dimensional Fund Advisors

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $761B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return